Amino Acid Sequence Disclosed In Whole Or In Part; Or Conjugate, Complex, Or Fusion Protein Or Fusion Polypeptide Including The Same Patents (Class 424/185.1)
  • Patent number: 10286050
    Abstract: Immunogenic T cell receptor ? alternate reading frame protein (TARP) peptide compositions that include multiple epitopes of the TARP protein are described. The disclosed compositions can be used for the treatment of TARP-expressing cancers, such as prostate cancer, breast cancer and mesothelioma. In some embodiments, the TARP peptide compositions disclosed herein include sets of overlapping TARP peptides that each have a length of about 15 to about 25 amino acids, and comprise about 5 to about 15 amino acids that are identical to at least another overlapping peptide in the set. In particular examples, the combination of the overlapping TARP peptides in the set encompasses the complete amino acid sequence of human TARP. The multi-epitope peptide compositions described herein include both CD4 and CD8 epitopes, a feature that is important for eliciting CD4+ T cell and CD8+ T cell, as well as humoral, immune responses.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: May 14, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Lauren V. Wood, Jay A. Berzofsky, Brenda D. Roberson, Masaki Terabe
  • Patent number: 10279026
    Abstract: NTHI protein antigens have been identified and found to be conserved across several Haemophilus influenzae pathogenic strains. They have been isolated, cloned from a reference strain and tested for immunogenicity. Methods for immunization and vaccines derived thereof are also disclosed.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: May 7, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Marco Soriani, Maria Scarselli, Nathalie Norais, Danilo Gomes Moriel, Silvia Rossi Paccani
  • Patent number: 10266574
    Abstract: The present disclosure provides fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: April 23, 2019
    Assignee: International AIDS Vaccine Initiative, Inc.
    Inventors: Ravi Anantha, Nathalie Cadieux, Thomas G. Evans, Michele Stone, Barry Walker
  • Patent number: 10258679
    Abstract: The present invention provides methods of treating, protecting against and inducing an immune response against a tumor or cancer, comprising the step of administering to a subject a recombinant Listeria strain. In one embodiment the present invention relates to a recombinant Listeria strain, said recombinant Listeria strain comprising a recombinant nucleic add, said nucleic add comprising a first open reading frame encoding a recombinant polypeptide comprising a first N-terminal fragment of an LLO protein fused to a heterologous antigen or fragment thereof, and wherein said recombinant nucleic add further comprises a second open reading frame encoding a mutant PrfA protein.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: April 16, 2019
    Assignee: ADVAXIS, INC.
    Inventors: Anu Wallecha, Robert Petit
  • Patent number: 10253077
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: April 9, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Valentina Goldfinger, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10253068
    Abstract: Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: April 9, 2019
    Assignee: Soligenix, Inc.
    Inventors: Oreola Donini, Annett Rozek, Jackson Lee, John North, Michael Abrams
  • Patent number: 10227611
    Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: March 12, 2019
    Assignees: The Regents of the University of California, University of Vienna
    Inventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
  • Patent number: 10226504
    Abstract: The present invention relates to novel formulations of soluble Fc receptors and especially to formulations containing high concentrations of soluble Fc?RIIB receptor. The invention further relates to the use of such formulations as pharmaceutical compounds for the treatment of autoimmune diseases, infections and other conditions where the immune system is involved.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: March 12, 2019
    Assignee: SUPPREMOL GMBH
    Inventors: Peter Sondermann, Thomas Pohl
  • Patent number: 10213475
    Abstract: The present invention relates to a peptide for preventing or treating inflammatory diseases and a use thereof. According to the novel dimeric peptide according to the present invention, it is possible to not only exhibit an excellent therapeutic effect through anti-inflammatory action but also have a very small-sized peptide, thereby minimizing side effects due to the administration of external substances and will be expected to be used as an active substance that can replace existing therapeutic agents for inflammatory diseases.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: February 26, 2019
    Assignee: BIO PEP CO., LTD.
    Inventors: Dae Ho Cho, Kyung Eun Kim, Sun Young Park, Youn Kyung Houh
  • Patent number: 10208086
    Abstract: Compositions and methods are provided for eliciting antigen-specific T-cell responses against human cyclin A1 (CCNA1), which is herein identified as a leukemia-associated antigen based on its overexpression in acute myeloid leukemia (AML) including leukemia stem cells (LSC) and in immunologically privileged testis cells, but not in other normal cell types. CCNA1-derived peptide epitopes that are immunogenic for T-cells including CTL are disclosed, as are immunotherapeutic approaches using such peptides for vaccines and generation of adoptive transfer therapeutic cells.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: February 19, 2019
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Philip Greenberg, Sebastian Ochsenreither
  • Patent number: 10202630
    Abstract: Methods for producing heterologous proteins are disclosed. In particular, the present disclosure provides improved methods of producing desired proteins, including multi-subunit proteins such as antibodies, with a higher yield and improved purity. In exemplary embodiments, the transformed cells are a yeast, e.g., methylotrophic yeast such as Pichia pastoris.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: February 12, 2019
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Gary Lesnicki, Mark Young
  • Patent number: 10195258
    Abstract: The present invention provides a cancer vaccine tape preparation for inducing cellular immunity, comprising: a support, an adhesive layer comprising an adhesive disposed on one side of the support, wherein the adhesive layer carries a combination of: (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a first cellular immunity induction promoter. The tape preparation can provides high efficacy.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: February 5, 2019
    Assignees: NITTO DENKO CORPORATION, OSAKA UNIVERSITY
    Inventors: Yoshiki Maeda, Katsuyuki Okubo, Daisuke Asari, Arimichi Okazaki, Takuya Shishido, Mitsuhiko Hori, Haruo Sugiyama
  • Patent number: 10190169
    Abstract: Disclosed are method and apparatus for identifying biomarkers and in particular for identifying biomarkers for use in making clinical assessments, such as early diagnostic, diagnostic, disease stage, disease severity, disease subtype, response to therapy or prognostic assessments. In one particular example, the techniques are applied to allow assessments of patients suffering from, suspected of suffering from, or with clinical signs of SIRS (Systemic Inflammatory Response Syndrome) being either infection-negative SIRS or infection-positive SIRS.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: January 29, 2019
    Assignee: ImmuneXpress Pty Ltd
    Inventors: Richard Bruce Brandon, Leo Charles McHugh
  • Patent number: 10190132
    Abstract: A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of influenza HA in plants and the purification by size exclusion chromatography. The invention is also directed towards a VLP comprising influenza HA protein and plant lipids. The invention is also directed to a nucleic acid encoding influenza HA as well as vectors. The VLPs may be used to formulate influenza vaccines, or may be used to enrich existing vaccines.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: January 29, 2019
    Assignee: MEDICAGO INC.
    Inventors: Marc-Andre D'Aoust, Manon Couture, Frederic Ors, Sonia Trepanier, Pierre-Olivier Lavoie, Michele Dargis, Louis-Philippe Vezina, Nathalie Landry
  • Patent number: 10191064
    Abstract: Provided are methods for determining the amount of thyroglobulin in a sample using various purification steps followed by mass spectrometry. The methods generally involve purifying thyroglobulin in a test sample, digesting thyroglobulin to form peptide T129, purifying peptide T129, ionizing peptide T129, detecting the amount of peptide T129 ion generated, and relating the amount of peptide T129 ion to the amount of thyroglobulin originally present in the sample.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: January 29, 2019
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Yanni Zhang, Nigel J. Clarke, Richard E. Reitz
  • Patent number: 10179174
    Abstract: The invention is related to peptide constructs, i.e., polypeptides obtained by linking together two or more peptides based on or derived from different molecules, which are useful in the treatment or prevention of influenza virus and other infectious diseases. Compositions containing the same, methods for producing the same, and methods for using the same are also disclosed, wherein the peptide constructs have the formula P1-x-P2, where P2 is a peptide associated with an infectious agent and P1 is a peptide that will bind to a class of immune cells, such as dendritic cells. The peptide construct can cause the maturation of immature dendritic cells to a more mature state. The peptide construct or the more mature dendritic cell can be administered to a subject to modulate or initiate an immune response against an infectious agent.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: January 15, 2019
    Assignee: Cel-Sci Corp.
    Inventors: Daniel H. Zimmerman, Eyal Talor, Kanta Subbarao, Kobporn Boonnak
  • Patent number: 10159725
    Abstract: The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against gastric cancers (GC).
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: December 25, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • Patent number: 10143658
    Abstract: Multistage delivery vehicles are disclosed which include a first stage particle and a second stage particle. The first stage particle is a micro or nanoparticle that contains the second stage particle. The second stage particle includes an active agent, such as a therapeutic agent or an imaging agent. The multistage delivery vehicle allows sequential overcoming or bypassing of biological barriers. The multistage delivery vehicle is administered as a part of a composition that includes a plurality of the vehicles. Methods of making the multistage delivery vehicles are also provided.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: December 4, 2018
    Assignees: Board of Regents of the University of Texas System, The Ohio State University Research Foundation
    Inventors: Mauro Ferrari, Ennio Tasciotti, Jason Sakamoto
  • Patent number: 10137183
    Abstract: This invention provides a cancer antigen peptide that can be administered to a wide range of cancer patients in the form of a peptide vaccine for cancer without the need for HLA typing and regardless of the HLA types of patients. Such peptide having 4 linked CTL epitopes is obtained by linking 4 CTL epitope peptides selected from among CTL epitope peptides derived from tumor antigen molecules that are reported to have the capacity for CTL induction via linkers.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: November 27, 2018
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Satoshi Fukaya, Toshihiro Osada, Hiroshi Wada
  • Patent number: 10137181
    Abstract: The invention relates to an peptide derived from a polymorphic region of donor MHC class II molecules which induces tolerance and thus prevents transplant rejection in a patient in need thereof. The invention relates to isolated peptide of length ranging between 11 and 16 amino acids comprising the amino acid sequence: SDVGEYR (SEQ ID NO: 1) or a function-conservative variant thereof for use as drug. The invention relates to an in vitro method for determining whether a transplanted patient is tolerant, comprising a step of determining the presence of CD8+CD45RClow Tregs in a biological sample obtained from said transplanted patient, wherein the presence of CD8+CD45RClow Tregs is indicative of tolerance.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: November 27, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉDE NANTES
    Inventors: Carole Guillonneau, Ignacio Anegon, Elodie Picarda
  • Patent number: 10113167
    Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: October 30, 2018
    Assignees: The Regents of the University of California, University of Vienna
    Inventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
  • Patent number: 10106786
    Abstract: Factor X/Xa variants and methods of use thereof are disclosed.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: October 23, 2018
    Assignee: The Children's Hospital of Philadelphia
    Inventor: Rodney M. Camire
  • Patent number: 10105425
    Abstract: The invention relates to an peptide derived from a polymorphic region of donor MHC class II molecules which induces tolerance and thus prevents transplant rejection in a patient in need thereof. The invention relates to an isolated peptide of 15 or 16 amino acids long that comprises or consists of the amino acid sequence: REEYARFDSDVGEYR (SEQ ID NO: 1) or a function-conservative variant for use as drug. The invention relates to an in vitro method for determining whether a transplanted patient is tolerant, comprising a step of determining the presence of CD8+CD45RClow Tregs in a biological sample obtained from said transplanted patient, wherein the presence of CD8+CD45RClow Tregs is indicative of tolerance.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: October 23, 2018
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Nantes
    Inventors: Carole Guillonneau, Ignacio Anegon, Elodie Picarda
  • Patent number: 10093717
    Abstract: The present invention relates to a chimeric antigen receptor, a nucleic acid encoding the same and a cell expressing the same, and their use in manufacturing drugs for treating tumors. The chimeric antigen receptor of the present invention is characterized by its intracellular domain including at least Toll-like receptor 1 and/or Toll-like receptor 2 intracellular domain(s); compared to the prior art, the chimeric antigen receptors of the present invention has significant advantages in T cell expansion, cytotoxicity, T cell invasion and migration, eliminating immunosuppressive effect of regulatory T cells and promoting the formation of memory T cells, etc.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: October 9, 2018
    Assignee: SHENZHEN IN VIVO BIOMEDICINE TECHNOLOGY LIMITED COMPANY
    Inventors: Peng Li, Yunxin Lai, Simiao Lin, Yao Yao
  • Patent number: 10081660
    Abstract: This invention refers to polynucleotides and non-hemorrhagic and non-immunogenic polypeptides of selective immunosuppressive activity on production of antibodies to antigens of different natures. The polypeptides described herein are useful for preparing pharmaceutical compositions for prevention or treatment of conditions that require immunosuppression, preferably, inflammatory, autoimmune, allergic and infectious diseases and rejection to transplanted organs.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: September 25, 2018
    Assignee: FUNDAÇÃO BUTANTAN
    Inventors: Denise V. Tambourgi, Giselle Pidde Queiroz, Osvaldo Augusto Brazil Esteves Sant'Anna, Fábio Carlos Magnoli, Ogari de Castro Pacheco
  • Patent number: 10077445
    Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: September 18, 2018
    Assignees: The Regents of the University of California, University of Vienna
    Inventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
  • Patent number: 10071146
    Abstract: This invention provides a cancer antigen peptide that can be administered to a wide range of cancer patients in the form of a peptide vaccine for cancer without the need for HLA typing and regardless of the HLA types of patients. Such peptide having 4 linked CTL epitopes is obtained by linking 4 CTL epitope peptides selected from among CTL epitope peptides derived from tumor antigen molecules that are reported to have the capacity for CTL induction via linkers.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: September 11, 2018
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Satoshi Fukaya, Toshihiro Osada, Hiroshi Wada
  • Patent number: 10071148
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to more than 70 novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: September 11, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Steffen Walter, Jens Fritsche, Colette Song, Harpreet Singh
  • Patent number: 10064918
    Abstract: The present invention provides for methods and compositions for treating or preventing arthritis and joint injury.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: September 4, 2018
    Assignee: Novartis AG
    Inventors: Lori Jennings, Kristen Johnson, Peter Schultz
  • Patent number: 10053494
    Abstract: Modified capsid proteins containing at least a portion of hepatitis E virus (HEV) open reading frame 2 (ORF2) having one or more cysteine residues in a surface variable loop or the C-terminus of HEV ORF2, or a portion thereof, are provided. The modified capsid proteins can be used to form hepatitis E virus (HEV) virus like particles (VLPs) having cysteine functional groups exposed on the outer-surface. The exposed cysteine functional groups can be modified via their thiol reactive group. For example, a bioactive agent, such as a cell-targeting ligand, can be conjugated to the one or more cysteines for targeted delivery of chemically activated nanocapsids.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: August 21, 2018
    Assignee: The Regents of the University of California
    Inventors: R. Holland Cheng, Li Xing, Chun Chieh Chen, Marie Stark
  • Patent number: 10052370
    Abstract: Protein conjugate comprising a protein antigen for generating an immune response against the HER2/neu protein and an immunogenic carrier covalently bonded to said protein antigen, wherein said protein antigen (i) has a sequence segment of 300 or more contiguous amino acids of the amino acid sequence of SEQ ID NO: 1; or (ii) has a variant sequence segment of 300 or more amino acid residues, wherein the amino acid sequence of said variant sequence segment has at least 85% sequence identity to a sequence portion from SEQ ID: 1; or (iii) has a variant sequence segment of 300 or more amino acid residues and has from 1 to 10 substitutions, deletions or additions in said variant sequence segment compared to a sequence segment of 300 or more amino acid residues of the amino acid sequence of SEQ ID NO: 1 or 2.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: August 21, 2018
    Assignees: ICON GENETICS GMBH, UNIVERSITY OF SOUTHAMPTON
    Inventors: Natalia Savelyeva, Franziska Jarczowski, Romy Kandzia, Anja Nickstadt, Frank Thieme, Victor Klimyuk, Yuri Gleba, Duc Bui-Minh, Freda K. Stevenson, Warayut Chotprakaikiat
  • Patent number: 10047124
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: August 14, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffen Walter, Harpreet Singh
  • Patent number: 10024868
    Abstract: The present invention provides novel methods and materials for efficiently treating patients having an HLA-B*0702 phenotype, based on peptides representing shared epitopes of tumor antigens. In particular, the invention relates to a method for identifying a HLA-B*0702-restricted peptide which can trigger a cytotoxic response against several antigens from one single multigenic family, and to several such epitopes.
    Type: Grant
    Filed: June 9, 2009
    Date of Patent: July 17, 2018
    Assignee: Vaxon Biotech
    Inventors: Kostantinos (Kostas) Kosmatopoulos, Jeanne Menez-Jamet
  • Patent number: 10022431
    Abstract: This document provides methods and materials related to treating cancer. For example, methods and materials for using nucleic acid libraries to treat cancer are provided.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: July 17, 2018
    Assignees: Mayo Foundation for Medical Education and Research, Leeds University
    Inventors: Richard G. Vile, Timothy J. Kottke, Jose S. Pulido, Alan Melcher, Peter Selby
  • Patent number: 10023648
    Abstract: In a first aspect, the present invention relates to genetically modified T-cells having a chimeric antigen receptor (CAR) in a method for adoptive cell therapy for treating TOSO+ cancer, like B-cell leukemia/lymphoma, in a subject in need thereof. In particular, the present invention relates to a genetically engineered T-cell containing and expressing a specific chimeric antigen receptor being toxic to TOSO+ cancer cells while being less toxic or non-toxic to TOSO+ non-cancer cells, in particular, being non-toxic to normal B cells and its precursors. In a further aspect, the present invention relates to a specific chimeric antigen receptor and the nucleic acid molecule encoding the same as well as vectors and cells containing the same.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: July 17, 2018
    Inventors: Andreas Hombach, Elena Faitschuk, Hinrich Abken
  • Patent number: 10005821
    Abstract: The present invention provides modified cupredoxin derived peptides with pharmacologic activity that have improved pharmacokinetic properties, and methods to use them to treat mammals suffering from various conditions related to the pharmacologic activities. Modifications of the cupredoxin derived peptides include amino acid sequence variants and structural derivations that increase the plasma half-life of the peptide, increase the specific activity of the pharmacologic activity, decrease immunogenicity, and decrease the biotransformation of the peptides. The modified cupredoxin derived peptides can be used in methods to treat mammals for cancer, conditions related to inappropriate angiogenesis, viral and bacterial infections, and specifically HIV and malaria, conditions related to ephrin signaling, and to deliver cargo compounds, including diagnostic compounds, to cancer cells.
    Type: Grant
    Filed: September 11, 2007
    Date of Patent: June 26, 2018
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Tapas Das Gupta, Ananda Chakrabarty
  • Patent number: 10005818
    Abstract: The present invention provides synthetic peptide compounds and uses thereof for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial and bacterial infections; and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human Astrovirus protein. In some embodiments, the invention is directed to peptide compounds that are peptide mimetics, peptide analogs and/or synthetic derivatives of PA (e.g., sarcosine derivatives) having, for example, internal peptide substitutions, and modifications, including PEGylation at the N-terminus and C-terminus. The invention further provides methods of selecting at least one synthetic peptide for treating various conditions.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: June 26, 2018
    Assignee: REALTA HOLDINGS, LLC
    Inventors: Neel K. Krishna, Kenji Cunnion
  • Patent number: 10006056
    Abstract: The present invention pertains to: mutant genes having a mutation such as a base substitution in the MTH1, GRR1 and/or CDC19 coding regions thereof; mutant proteins coded by said mutant genes; an upstream region of the GRR1 coding region having a mutation such as a base substitution; a yeast such as Saccharomyces having said upstream region; and a method for producing a substance such as ethanol by using said yeast.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: June 26, 2018
    Assignee: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
    Inventors: Satoru Ohgiya, Yoichi Kamagata, Kazuhiro Fujimori, Takehiko Sahara, Takashi Akamatsu, Hisataka Taguchi
  • Patent number: 10000538
    Abstract: The invention provides a L19 source as a medicament, preferably for preventing or treating an inflammatory disorder in an individual.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: June 19, 2018
    Assignee: LABORATORIOS LETI, S.L.
    Inventors: Carlos Alonso-Bedate, Manuel Soto-Alvarez, Laura Ramirez-Garcia, Jeronimo Carnés-Sánchez, Marta Román-Escutia
  • Patent number: 9993523
    Abstract: A method of treating a patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer. A method of treating a patient who has cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the cancer.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: June 12, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • Patent number: 9993546
    Abstract: The invention provides chimeric proteins and nucleic acids encoding these which can be used to generate vaccines against selected antigens. In one aspect, a chimeric protein comprises an antigen sequence and a domain for trafficking the protein to an endosomal compartment, irrespective of whether the antigen is derived from a membrane or non-membrane protein. In one preferred aspect, the trafficking domain comprises a lumenal domain of a LAMP polypeptide. Alternatively, or additionally, the chimeric protein comprises a trafficking domain of an endocytic receptor (e.g., such as DEC-205 or gp200-MR6). The vaccines (DNA, RNA or protein) can be used to modulate or enhance an immune response against any kind of antigen. In one preferred aspect, the invention provides a method for treating a patient with cancer by providing a chimeric protein comprising a cancer-specific antigen or a nucleic acid encoding the protein to the patient.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: June 12, 2018
    Assignee: The Johns Hopkins University
    Inventors: Thomas August, Ernesto Marques, Jr.
  • Patent number: 9974793
    Abstract: Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: May 22, 2018
    Assignee: Heron Therapeutics, Inc.
    Inventors: Thomas B. Ottoboni, Han Han
  • Patent number: 9962437
    Abstract: Compositions, methods, and kits for inhibiting an allergic response against an allergenic protein are disclosed. Compositions, methods and kits for inhibiting an allergic response against a flea allergenic protein; a feline allergenic protein; a canine allergenic protein; a dust mite allergenic protein; a peanut allergenic protein; a Japanese cedar allergenic protein; and a blomia tropicalis allergenic protein are disclosed.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: May 8, 2018
    Inventors: Bin Wang, Huali Jin, Youmin Kang, Hsien-Jue Chu, Terry Kaleung Ng
  • Patent number: 9950056
    Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: April 24, 2018
    Inventors: John H. Sampson, Duane A. Mitchell
  • Patent number: 9944684
    Abstract: The disclosure provides an antigenic peptide targeting the extracellular, but not the intracellular, form of CETP to reduce the level of LDL (including oxLDL and other derivatives of LDL) and increase the level of HDL. Accordingly, the disclosure provides a CETP vaccine to overcome the low immunogenicity of CETP and for long-term inhibition of CETP activity to prevent or treat oxLDL or other LDL derivative-related diseases/symptoms.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: April 17, 2018
    Assignee: Taipei Medical University
    Inventor: Jaulang Hwang
  • Patent number: 9945864
    Abstract: The present disclosure provides synthetic antibodies specific for a disease-associated antigen, and methods of using the antibodies in disease therapy. The present disclosure further provides diagnostic assays involving detecting the presence and/or level in biological sample of an antibody specific for a disease-associated antigen.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: April 17, 2018
    Assignee: The Regents of the University of California
    Inventors: Lawrence H. Fong, Serena Kwek MacPhee
  • Patent number: 9926350
    Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: March 27, 2018
    Assignee: VAR2 PHARMACEUTICALS APS
    Inventors: Ali Salanti, Thor Grundtvig Theander, Mads Daugaard, Morten Nielsen, Madeleine Dahlback, Thomas Mandel Clausen
  • Patent number: 9920096
    Abstract: The present invention relates generally to novel biological and purified peptides as bradykinin receptor modulators for use in the treatment and/or prevention of inflammatory diseases, pain, hyperalgesia, cardiovascular and/or cerebral ischemic diseases, in a subject in need thereof.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: March 20, 2018
    Inventor: Jair Ribeiro Chagas
  • Patent number: 9919030
    Abstract: In certain aspects, the present invention provides methods for dosing a patient with a follistatin antagonist and methods for managing patients treated with a follistatin antagonist.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: March 20, 2018
    Assignee: ACCELERON PHARMA INC.
    Inventor: Matthew L. Sherman
  • Patent number: RE47164
    Abstract: The present invention relates to the field of Streptococcus. More specifically, the present invention relates to the identification of polypeptides and polynucleotide sequences encoding the same which are involved in the pathogenic mechanism of S. suis. The present invention also relates to the use of such polypeptides in compositions and methods for the prevention, the treatment and diagnosis of S. suis-associated diseases and infections caused by S. suis.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: December 18, 2018
    Assignee: Valorisation-Recherche Limited Partnership
    Inventors: Josee Harel, Marcelo Gottschalk, Yuanyi Li